In this article (Mol Can Ther 2012;11:763–74), which was published in the March 2012 issue of Molecular Cancer Therapeutics (1), the authors regret that an error during the assembly of the final figure panel for Fig. 3D resulted in duplication of the β-actin across the C and D panels of this figure. The authors state that the error does not change the scientific content, interpretations, or conclusions of the article. The correct β-actin panel for Fig. 3D is shown below.

Figure 3.

MLN8237 and CDDP combination treatment significantly inhibits cell survival and enhances apoptosis. A and B, the cell survival assay data indicate significant inhibition of FLO-1 and OE33 esophageal adenocarcinoma cell survival after treatment with MLN8237 and CDDP combination. C and D, FLO-1 and OE33 esophageal adenocarcinoma cells were treated with MLN8237 (0.5 μmol/L) and/or CDDP (2.5 μmol/L) for 24 hours and incubated in drug-free medium for 48 hours. Subsequently, expression of apoptotic proteins and TAp73β activity was evaluated. MLN8237 (0.5 μmol/L) and CDDP (2.5 μmol/L) combination treatment significantly enhanced expression of apoptotic proteins and mRNA levels of TAp73β proapoptotic transcriptional targets, PUMA and NOXA, in esophageal adenocarcinoma cells. CDDP 2.5, 2.5 μmol/L cisplatin; CDDP 5.0, 5.0 μmol/L cisplatin; CV, control vehicle; and MLN 0.5, 0.5 μmol/L MLN8237. *, P < 0.05; **, P < 0.01.

Figure 3.

MLN8237 and CDDP combination treatment significantly inhibits cell survival and enhances apoptosis. A and B, the cell survival assay data indicate significant inhibition of FLO-1 and OE33 esophageal adenocarcinoma cell survival after treatment with MLN8237 and CDDP combination. C and D, FLO-1 and OE33 esophageal adenocarcinoma cells were treated with MLN8237 (0.5 μmol/L) and/or CDDP (2.5 μmol/L) for 24 hours and incubated in drug-free medium for 48 hours. Subsequently, expression of apoptotic proteins and TAp73β activity was evaluated. MLN8237 (0.5 μmol/L) and CDDP (2.5 μmol/L) combination treatment significantly enhanced expression of apoptotic proteins and mRNA levels of TAp73β proapoptotic transcriptional targets, PUMA and NOXA, in esophageal adenocarcinoma cells. CDDP 2.5, 2.5 μmol/L cisplatin; CDDP 5.0, 5.0 μmol/L cisplatin; CV, control vehicle; and MLN 0.5, 0.5 μmol/L MLN8237. *, P < 0.05; **, P < 0.01.

Close modal
1.
Sehdev
V
,
Peng
D
,
Soutto
M
,
Washington
MK
,
Revetta
F
,
Ecsedy
J
, et al
The aurora kinase A inhibitor MLN8237 enhances cisplatin-induced cell death in esophageal adenocarcinoma cells
.
Mol Can Ther
2012
;
11
:
763
74
.